Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Processing

Read more breaking news



Pharma needs to rethink supply chains in an era of patent expiry and global outsourcing

By Gareth Macdonald , 26-Mar-2012
Last updated on 26-Mar-2012 at 14:29 GMT2012-03-26T14:29:42Z

Pharma needs to rethink supply chains in an era of patent expiry and global outsourcing
Pharma needs to rethink supply chains in an era of patent expiry and global outsourcing

Planning supply chains early is an important part of maintaining margins but is often overlooked by Pharmas too focused on developing the next product in an era of patent expiry says industry consultant. spoke with Hedley Rees from Biotech Pharmaflow who said that the supply chain is critical to delivering a value pharmaceutical product to the marketplace which – in turn – is vital for revenue generation.

Any business which wants to maintain sustainable competitive advantage has to be able to provide customers with sustainable, quality products. A lot of the issues that we have with patent expiries exist because the industry has not done the underpinning work to increase effectiveness and efficiency… so that it can make good margins on what it supplies to patients.”

Rees went on suggest that, instead of supply chain efficiency, the drug industry has focused on bringing new products to market as quickly as possible to maintain revenues thereby missing out on the easy wins that are provided by simply doing the basics better.

He also voiced concerns about outsourcing, arguing that drugmakers efforts to find the best deal have created supply chains that are complex, disconnected and inefficient and – ironically given the original motivation – can lock manufacturers into cost escalation and inefficient processes.

As we develop drugs – for some reason - developers  seem to go all over the world to make their various products and…tend not to take a strategic view of sourcing so we find very often that API and excipient suppliers do not get involved until too late.”

Solution, engagement and planning

The solution – according to Rees  - is modernisation, who believes that instead of a ‘mass production’ approach the drug sector needs to adopt a lean model like the automotive industry – which, for example, puts the responsibility for quality on the person making each product.

He also thinks that drugmakers need to engage with suppliers and form closer bonds with contractors for the greatest efficiency gains.

"If we engage in the reintegration of the supply chain or build strong strategic partnerships with contract manufacturers, contract research organisations and logistics services providers...we would see much less complex supply chains with fewer compliance gaps and it would be much more difficult for criminals to damage the industry through counterfeiting."

Hedley Rees is a practising consultant, coach and trainer in Pharmaceutical Operations and Supply Chain Management.   His enduring interest is in driving industry improvements through the regulatory modernization frameworks of FDAs 21st Century Modernization and ICH Q8 – Q11.

His book “Supply Chain Management in the Drug Industry: Delivering Patient Value for Pharmaceuticals and Biologics” can be purchased here .

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

ASI has teamed up with Chromatan in order to deliver single-use and column-free capture...

Updated IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests

John Giannone - incoming IPEC-Americas chairman

Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

Special Report from ATMI's Belgian Facility

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

Walter Dissinger

President , BASF nutrition and health

Optimism is returning to the pharma fine chemicals sector, says analyst

Jan Ramakers

Industry consultant, Jan Ramakers Fine Chemical Consulting Group

Capsugel expands liquid fill capsule capabilities

Keith Hutchison,

Senior VP of research and development (R&D) , Capsugel

New filtration tech boosts biomanufacturing yields, says Sartorius

Jens Meyer

Product manager for filtration technologies, Sartorius Stedim

Submit good REMS proposals for FDA brownie points, says RAPS author

Ed Tabor

VP of strategic drug development , Quintiles

Happy Holidays 2014 from William Reed Business Media!

The holidays are fast upon us, so let’s put ‘business’ to one side and...

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Missy Lowery

Marketing Manager for the Americas, Capsugel

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Cory Stevenson & Brandon Pence

Thermo Fisher Scientific

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

Eric Isberg

Global Product Manager, ATMI

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the...

Key Industry Events


Access all events listing

Our events, Shows & Conferences...